Shasqi presents two posters at The Connective Tissue Oncology Society 25th Anniversary Annual Meeting showcasing their lead candidate SQ3370.

In their preclinical poster, Shasqi shows that SQ3370 induces a dose-dependent, sustained local and systemic anti-tumor response in dual-tumor syngeneic murine models of colon adenocarcinoma, fibrosarcoma and melanoma. Additional pharmacological outcomes suggest SQ3370 activates an immune-mediated response in both treated and untreated tumors. The treatment also demonstrated a favorable toxicity profile as it did not induce body weight losses, even at the highest administered dose.

In addition, Shasqi presents a trial-in-progress poster on a first-in-human phase I study for their lead candidate SQ3370, a click activated protodrug therapy. SQ3370 is the first click chemistry-based treatment to be used in humans. The study SQ3370-001 is currently enrolling patients with advanced sarcomas and other solid tumors in the United States and Australia (ClinicalTrials.gov Identifier NCT04106492).

‍